1. Market Research
  2. > Healthcare
  3. > Health Services Market Trends
Wet Macular Degeneration- Market Insight, Epidemiology and Market Forecast -2030

Wet Macular Degeneration- Market Insight, Epidemiology and Market Forecast -2030

  • February 2021
  • 215 pages
  • ID: 6028035
  • Format: PDF
  • Delve Insight


Table of Contents

‘Wet-Age-related Macular Degeneration (Wet-AMD)—Market Insights, Epidemiology, and Market Forecast—2030’ report deliver an in-depth understanding of the Wet-AMD, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Wet-AMD market report provides current treatment practices, emerging drugs, and their market share of the individual therapies, current and forecasted Wet-AMD symptoms market size from 2017 to 2030 segmented by seven major markets. The report also covers current Wet-AMD symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities. It assesses the underlying potential of the market.

Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2017–2030

Wet-AMD Disease Understanding and Treatment Algorithm

Wet-AMD Overview
Age-related macular degeneration (AMD) is a leading cause of severe, irreversible blindness in developed countries worldwide, profoundly affecting the quality of life of affected individuals. With the increase in life expectancy bringing growth in the number of reported cases, it adds a significant burden on the health care systems with the expensive current standard of care. Wet-AMD is a type of AMD which is characterized by abrupt central vision loss caused by abnormal blood vessels that bleed or leak fluid which may swell and damage the macula. Wet-AMD also referred to as neovascular AMD, accounts for roughly 10% of AMD cases, but almost 90% of AMD-related central vision loss. Although 80 percent of the patients have non-neovascular, or atrophic AMD, the neovascular form of the disease is responsible for nearly 90 percent of the severe, central visual acuity loss associated with AMD.
AMD’s progression leads to loss of central vision, which adversely affects the quality of life. Although AMD’s exact functional pathogenesis is not fully understood, there have been recent improvements in genetic technologies leading to the identification of various polymorphisms that have shown to harbor unique associations with AMD.

Wet-AMD Diagnosis and Treatment
It covers the details of conventional and current medical therapies and diagnosis available in the Wet-AMD market for the treatment of the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.
The Wet-AMD market report gives a thorough understanding of WET-AMD symptoms by including details such as disease definition, symptoms, causes, physiology, and diagnosis. It also provides WET-AMD symptoms of treatment algorithms and treatment guidelines for WET-AMD symptoms in the US, Europe, and Japan.
Diagnosing AMD involves differentiating macular aging changes from degenerative abnormalities that threaten, or are affecting vision. In particular, the identification of wet AMD is important, as timely and appropriate treatment can save sight. Patients with wet AMD often have symptoms that can alert healthcare professionals to a macular problem rather than non-specific “blurry vision.” Those with the skills and equipment to examine the macula can also find signs suggestive of wet AMD. AMD’s clinical diagnosis is typically made during the retina examination by an eye care provider. Key features include deep RPE pigmentary changes, sub-retinal fluid or fibrosis, macular edema, and hemorrhage or exudate.
Photodynamic therapy (PDT) with verteporfin has been tested in several prospective studies for the treatment of various subtypes of exudative, subfoveal AMD. In 2000, the United States Food and Drug Administration (FDA) approved PDT with verteporfin for the treatment of predominantly classic, subfoveal choroidal neovascularization. However, due to several limitations, an alternate treatment regime was needed. Thus the development of anti-VEGF substances to treat wet AMD can be considered a milestone. Several anti-VEGF therapies are now available in the market which has significantly improved patient’s lives. The major players include Lucentis, Eylea, Bevacizumab, and Beovu.

Wet-AMD Epidemiology
The Wet-AMD symptoms epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings
The total prevalent cases of Wet-AMD is increasing in 7MM during the study period, i.e., 2017–2030.
The disease epidemiology covered in the report provides historical as well as forecasted Wet-AMD symptoms epidemiology segmented as the Total Prevalent cases of Wet-AMD, Gender-specific cases of Wet-AMD, and Age-specific cases of Wet-AMD. The report includes the prevalent scenario of Wet-AMD symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country-wise Wet-AMD Epidemiology
The epidemiology segment also provides the Wet-AMD epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The total prevalent cases of Wet-AMD associated in 7MM countries was 4,426,968 in 2020.

Wet-AMD Drug Chapters
The drug chapter segment of the Wet-AMD report encloses the detailed analysis of Wet-AMD early-stage (Phase- I, II, and III) pipeline drugs. It also helps understand the Wet-AMD clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
Wet-AMD Emerging Drug
Faricimab: Roche
Faricimab (RG7716), the first bispecific antibody developed with CrossMab technology, is designed specifically for intravitreal use to simultaneously bind to and neutralize both angiopoietin-2 (Ang-2) and VEGF-A with high potency and specificity. In nAMD, Ang-2 works synergistically with VEGF to drive pathologic blood vessel permeability and destabilization, abnormal blood vessel growth, and fluid leakage, which contribute to vision loss. Ang-2 also plays a vital role in multiple aspects of inflammation in neovascular Age-related macular degeneration (nAMD). Currently, two Phase III clinical trials are evaluating faricimab for the treatment of nAMD.
KSI-301: Kodiak Sciences
KSI-301 is a novel anti-VEGF biologic designed to rapidly inhibit VEGF and provide extended durability of action to reduce the burden of frequent anti-VEGF injections. Delivering potent and sustained VEGF inhibition enables patient compliance, results in long-term efficacy, and improves visual acuity outcomes.
Products detail in the report…

Wet-AMD Market Outlook
The Wet-AMD market outlook of the report helps build a detailed comprehension of the historic, current, and forecasted Wet-AMD market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of Wet-AMD market trend of each marketed drug and early-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to the analyst, the Wet-AMD market in 7MM is expected to grow in the study period 2017–2030.
Past studies have found that just one year after diagnosis, less than 15 percent of patients given this therapy alone retain 20/40 vision, and up to 40 percent decline to 20/200 vision. However, the advances in medical research have identified the Vascular Endothelial Growth Factor (VEGF) as a key pathophysiological factor in the development of neovascular AMD, with an essential role in angiogenesis, vascular permeability, and inflammatory response. The introduction of anti-VEGF intravitreal injections has opened a new therapeutic window in the management of wet AMD, thus efficiently blocking the pathophysiological process of AMD, with a restoration of retinal morphology and the maintenance of its function. In the past years, anti-VEGF injections have become the standard treatment for wet AMD, accounting for better results than the previous choices, such as photodynamic therapy (PDT) and laser photocoagulation.

Key Findings
This section includes a glimpse of the Wet-AMD market in 7MM.
The market size of Wet-AMD in the seven major markets was USD 7,459 million in 2020.

The United States Market Outlook
This section provides the total Wet-AMD market size and market size by therapies in the United States.
The United States accounts for the largest market size of Wet-AMD in comparison to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

EU-5 Countries: Market Outlook
The total Wet-AMD market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook
The total Wet-AMD market Size and market Size by therapies in Japan are also mentioned.

Wet-AMD Drugs Uptake
This section focuses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2017–2030. The analysis covers Wet-AMD market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs based on market share and size which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Wet-AMD Pipeline Development Activities
The report provides insights into the therapeutic candidate in Phase I, II, and III stages. It also analyses Wet-AMD key players involved in developing targeted therapeutics.
Major players include Roche, Kodiak Sciences, Opthea Limited, Alkahest, Graybug Vision, REGENXBIO, and Chengdu Kanghong Biotech.

Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Wet-AMD emerging therapies.
Reimbursement Scenario in Wet-AMD
Approaching reimbursement, proactively, can have a positive impact both during the early stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

The Patient Assistance Program may help eligible patients get EYLEA free of charge if you are uninsured or if their health plan does not cover EYLEA. To qualify, one must: - a) Be uninsured or lack coverage for EYLEA, b) Live in the United States or its territories or possessions, c) Show financial need (based on total annual household adjusted gross income)
Medicare Part B covers ophthalmology services that are reasonable and necessary for diagnosing or treating illness or injury or improving a malformed body member’s functioning. Ophthalmology services include Eylea and Lucentis’s intravitreal injections to treat eye diseases such as wet age-related macular degeneration. Medicare pays for an intravitreal injection (which is considered a minor surgery) as part of a global surgical package that includes the preoperative, intraoperative, and postoperative services routinely performed by the physician. Medicare pays for Eylea and Lucentis separately from the intravitreal injection. Chapter 12, section 40.1 of the Centers for Medicare & Medicaid Services’ Medicare Claims Processing Manual states that separate payment can be made for other services provided by the same physician on the same day as the global surgery if the services are significant and separately identifiable or unrelated to the surgery.
KOL Views
To keep up with current market trends, we take KOLs and SME’s opinion working in the Wet-AMD domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging therapies treatment patterns or Wet-AMD market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis
We perform a Competitive and Market Intelligence analysis of the Wet-AMD Market by using various Competitive Intelligence tools that include – SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report
• The report covers the descriptive overview of Wet-AMD, explaining its causes, signs and symptoms, physiology, and currently available therapies.
• Comprehensive insight has been provided into the Wet-AMD epidemiology and treatment in the 7MM.
• Additionally, an all-inclusive account of both the current and emerging therapies for Wet-AMD is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
• A detailed review of the Wet-AMD market; historical and forecasted is included in the report, covering drug outreach in the 7MM.
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Wet-AMD market.

Report Highlights
• In the coming years, the Wet-AMD market is set to change due to the rising awareness of the disease, and the Favorable Environment for New Anti-infective Modalities; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence Wet-AMD R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Major players are involved in developing therapies for Wet-AMD. The launch of emerging therapies will significantly impact the Wet-AMD market.
• Our in-depth analysis of the pipeline assets across different stages of development (Phase I, II, and III), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, and launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Wet-AMD Report Insights
• Patient Population
• Therapeutic Approaches
• Wet-AMD Pipeline Analysis
• Wet-AMD Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Wet-AMD Report Key Strengths
• 11 Years Forecast
• 7MM Coverage
• Wet-AMD Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market

• Drugs Uptake

Wet-AMD Report Assessment
• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Questions

Market Insights:
• What was the Wet-AMD Market share (%) distribution in 2017 and how it would look like in 2030?
• What would be the Wet-AMD total market Size as well as market Size by therapies across the 7MM during the forecast period (2017–2030)?
• What are the key findings of the market across 7MM and which country will have the largest Wet-AMD market Size during the forecast period (2017–2030)?
• At what CAGR, the Wet-AMD market is expected to grow in 7MM during the forecast period (2017–2030)?
• What would be the Wet-AMD market outlook across the 7MM during the forecast period (2017–2030)?
• What would be the Wet-AMD market growth till 2030, and what will be the resultant market Size in the year 2030?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:
• What are the disease risk, burden, and unmet needs of the Wet-AMD?
• What is the historical Wet-AMD patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of Wet-AMD in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What will be the growth opportunities in the 7MM concerning the patient population about Wet-AMD?
• Out of all 7MM countries, which country would have the largest prevalent population of Wet-AMD during the forecast period (2017–2030)?
• At what CAGR the population is expected to grow in 7MM during the forecast period (2017–2030)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
• What are the current options for the treatment of Wet-AMD along with the approved therapy?
• What are the current treatment guidelines for the treatment of Wet-AMD in the USA, Europe, and Japan?
• What are the Wet-AMD marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
• How many companies are developing therapies for the treatment of Wet-AMD?
• How many therapies are developed by each company for the treatment of Wet-AMD?
• How many emerging therapies are in the mid-stage and late stages of development for the treatment of Wet-AMD?
• What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Wet-AMD therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Wet-AMD and their status?
• What are the key designations that have been granted for the emerging therapies for Wet-AMD?
• What are the global historical and forecasted market of Wet-AMD?

Reasons to buy
• The report will help in developing business strategies by understanding trends shaping and driving the Wet-AMD market.
• To understand the future market competition in the Wet-AMD market and Insightful review of the key market drivers and barriers.
• Organize sales and marketing efforts by identifying the best opportunities for Wet-AMD in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Organize sales and marketing efforts by identifying the best opportunities for the Wet-AMD market.
• To understand the future market competition in the Wet-AMD market.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Ophthalmic Medical Lasers Global Market Report 2021: COVID 19 Growth And Change to 2030

  • $ 5000
  • May 2021
  • 175 pages

Major players in the ophthalmic medical lasers market are Alcon Laboratories Inc, Abbott Medical Optics Inc., Carl Zeiss Meditec AG, Bausch & Lomb Incorporated, Topcon Corporation, Ziemer Ophthalmic Systems ...

  • France
  • Australia
  • Ophthalmology
  • Eye Disease
  • Industry analysis
  • Health Provider Density


Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on